60 Minute Audio Conference presented by Karin Rodland, PH.D
Mandatory NIH Short Form Changes – Are you prepared to incorporate NIH’s changes into your grant writing?
Changes which include; an exclusion of the written summary, reviewing begins with high scores not random selections, section strengths and weaknesses are limited to a half of a page, cutting the number of applications discussed, and more. In short, these changes affect every grant application – learn what you can do to improve your grant approval chances.
Now more than ever, grant writing is an essential part of every application. Jump-start your knowledge on NIH’s shortened application by attending this audio conference. Utilize fool-proof methods to improve your application skills by learning effective writing techniques. Take advantage of your expert speaker’s experience as a long-time NIH reviewer to learn tips of how to navigate the new NIH short form. Walk away with pointers you can use to make your NIH short form grant application work for you.
Get the inside scoop on the following hot topics:
- How to combine new elements to form a winning Research Strategy
- Explanation of the revised 5 areas of peer review criteria
- Resources vs. Boilerplate elements
- Which publications to include in your biosketch
- Scoring changes – what does it mean to your grant?
Who should listen?
Early Stage Principal Investigators, Grant Officers, Grant Administrators, Office of Research Services, and anyone else involved in the process of writing winning grant proposals.
The Principal Investigators Association, an independent organization, brings you this product as a training tool. The content has no connection with the NIH or NSF, nor do these agencies endorse it. All views expressed are those personally held by the author and are not official government policies or opinions. SHOW LESS READ MORE >
Dr. Karin Rodland, Laboratory Fellow, Biological Sciences Division, Richland, Washington.
Dr. Rodland’s research is focused on mechanisms of signal transduction in normal cells and how these mechanisms are altered in cancer cells. She has been an NIH reviewer since 1998.
Dr. Rodland was an associate professor in the department of cell and developmental biology at Oregon Health Sciences University from 1985-2001. She retains her status as member of the Oregon Cancer Institute and as a collaborating scientist at the Oregon Regional Primate Research Center.